TIL

Business Context and Reporting Period

Instil Bio, Inc. (TIL) is a clinical-stage biopharmaceutical company focused on developing novel therapies, primarily its lead product candidate AXN-2510/IMM2510 ('2510), a PD-L1xVEGF bispecific antibody for solid tumors. The company operates as a single segment and is classified as an emerging growth company and smaller reporting company. This summary covers the quarterly period ended September 30, 2025.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company has no product revenue.

Material Changes vs. Prior Period

• Net Loss Improvement (Q3): Net loss decreased by $9.4 million year-over-year in Q3 2025, driven primarily by a $10.0 million reduction in in-process research and development (IPR&D) expenses and a $2.4 million decrease in restructuring charges.
• Restructuring and Impairment (9M): Restructuring and impairment charges increased significantly to $16.6 million for the nine months ended September 30, 2025, compared to $7.1 million in the prior year. This increase was primarily due to a $16.6 million impairment charge related to the Tarzana facility being classified as held for sale.
• R&D Expenses: Research and development expenses increased to $9.1 million in Q3 2025 from $0.6 million in Q3 2024, reflecting increased clinical development activities for the '2510 program following the in-license from ImmuneOnco.
• Rental Income: Other rental income increased to $2.2 million in Q3 2025 from $1.5 million in Q3 2024, attributable to the lease of the Tarzana facility to AstraZeneca.
• Balance Sheet: Total assets decreased to $211.8 million from $263.6 million at year-end 2024, largely due to the reclassification of the Tarzana facility ($112.1 million) to "Assets held for sale" and the associated impairment.

Guidance, Outlook, and Risks

• Clinical Progress: The company initiated a Phase 1 clinical trial of '2510 in the U.S. in October 2025. Collaborator ImmuneOnco reported preliminary efficacy data from Phase 1 and Phase 2 trials in China, showing objective response rates of 35.3% in squamous NSCLC (Phase 1) and 62% in a Phase 2 combination trial.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($83.4 million) are sufficient to fund operations beyond 2026. The company has an At-The-Market (ATM) program with approximately $93.1 million remaining availability.
• Tarzana Facility Sale: The Tarzana facility is listed for sale. A successful sale could extend the company's cash runway, but there is no assurance of a sale or the timing thereof.
• Key Risks:
  • Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional funding.
  • Regulatory Uncertainty: Success depends on regulatory approval of '2510, which is in early-stage development. Data from China-based trials may not be accepted by the FDA.
  • Collaboration Dependence: The company relies on ImmuneOnco for manufacturing and clinical data generation in China.
  • Asset Impairment: Risk of further impairment losses if the Tarzana facility is not sold or is sold for less than its carrying value.

Investor Verification Checklist

• Verify the status and timeline of the sale of the Tarzana facility and its impact on the $85.6 million secured debt.
• Confirm the enrollment progress and data readout dates for the U.S. Phase 1 trial of '2510 initiated in October 2025.
• Assess the sufficiency of the $83.4 million liquidity position against projected R&D burn rates for the '2510 program.
• Review the terms of the ImmuneOnco collaboration regarding future milestone payments and royalty obligations.
• Monitor the company's ability to raise additional capital via the ATM program or other equity/debt offerings given the lack of product revenue.